PMID- 26899763
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20221207
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 212
IP  - 4
DP  - 2016 Apr
TI  - HER-2, ER, PR status concordance in primary breast cancer and corresponding 
      metastatic lesion in lymph node in Chinese women.
PG  - 252-7
LID - S0344-0338(15)30050-9 [pii]
LID - 10.1016/j.prp.2015.11.019 [doi]
AB  - AIMS AND BACKGROUND: To compare the expression of estrogen receptor (ER), 
      progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) 
      in the primary site and the metastatic lesion of lymph nodes in invasive breast 
      cancer for investigating whether the expression of these biomarkers in the 
      primary site could act as a surrogate to the lymphatic metastatic lesion in the 
      same patient. METHODS: In lymphatic metastatic lesion and corresponding primary 
      lesion of 107 cases of invasive breast cancer, ER and PR statuses were assessed 
      by immunohistochemistry (IHC). HER-2 expression level was evaluated by IHC and/or 
      fluorescence in situ hybridization (FISH). RESULTS: In the primary lesions, 43.9% 
      were ER positive; 46.7% were PR positive; 34.6% were HER-2 positive. In 
      corresponding lymphatic metastatic lesions, the HER-2 status was concordant in 90 
      patients; 9 patients were diagnosed positive in metastatic lesion while negative 
      in primary lesion; 8 patients were negative in metastatic lesion while positive 
      in primary site (agreement, 84.1%; kappa=0.647). A change in ER status was observed 
      in 24 cases: 17 cases positive in metastatic site while negative in primary site; 
      7 cases negative in metastatic site while positive in primary site (agreement, 
      77.6%; kappa=0.534). PR status discordance between the primary lesion and the 
      metastatic regional lymph nodes was reported in 19 cases (agreement, 82.2%; 
      kappa=0.640). CONCLUSIONS: This study revealed that there was only a moderate 
      concordance of ER, PR and HER-2 status between primary tumors and metastatic 
      lymph nodes. These results indicate that it was inappropriate to predict the 
      status of ER, PR and HER-2 in metastatic lymph nodes based on the results of 
      evaluation of that in primary lesions.
CI  - Copyright (c) 2015 Elsevier GmbH. All rights reserved.
FAU - Li, Min Hua
AU  - Li MH
AD  - Department of Pathology, Shaoxing People's Hospital & Shaoxing Hospital of 
      Zhejiang University, Shaoxing, Zhejiang, China.
FAU - Hou, Chuan Ling
AU  - Hou CL
AD  - Department of Pathology, Shaoxing People's Hospital & Shaoxing Hospital of 
      Zhejiang University, Shaoxing, Zhejiang, China.
FAU - Wang, Cheng
AU  - Wang C
AD  - Department of Pathology, Shaoxing People's Hospital & Shaoxing Hospital of 
      Zhejiang University, Shaoxing, Zhejiang, China.
FAU - Sun, Ai Jing
AU  - Sun AJ
AD  - Department of Pathology, School of Medicine, Shaoxing University, Shaoxing, 
      Zhejiang, China. Electronic address: minhuali19810816@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160201
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis/*pathology
MH  - Middle Aged
MH  - Receptor, ErbB-2/analysis/biosynthesis
MH  - Receptors, Estrogen/analysis/biosynthesis
MH  - Receptors, Progesterone/analysis/biosynthesis
MH  - Young Adult
OTO - NOTNLM
OT  - Breast cancer
OT  - ER
OT  - HER-2
OT  - Metastatic lymph nodes
OT  - PR
EDAT- 2016/02/24 06:00
MHDA- 2017/01/28 06:00
CRDT- 2016/02/23 06:00
PHST- 2014/06/19 00:00 [received]
PHST- 2015/11/22 00:00 [revised]
PHST- 2015/11/27 00:00 [accepted]
PHST- 2016/02/23 06:00 [entrez]
PHST- 2016/02/24 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
AID - S0344-0338(15)30050-9 [pii]
AID - 10.1016/j.prp.2015.11.019 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2016 Apr;212(4):252-7. doi: 10.1016/j.prp.2015.11.019. Epub 
      2016 Feb 1.